Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START UP: upadacitinib versus dupilumab in children with moderate-to-severe atopic dermatitis
MOH_2024-07-10_013517Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of upadacitinib and dupilumab in atopic dermatitis (AD) (4 cohorts), sponsored by AbbVie Inc. Primary endpoint: Not reported. Started Jul 2024; status: recruiting.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2024-07-10_013517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-10_013517.